Leap Therapeutics, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
LPTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
47 Thorndike Street, Suite B1 1, Cambridge, MA

There are no Buy or Sell transactions made by insiders since 4/23/2024

Leap Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
BeiGene, Ltd. 10%+ Owner $20.9M Sep 24, 2021
Gilead Sciences, Inc. 10%+ Owner $15.2M Apr 10, 2024
Perceptive Advisors Llc 10%+ Owner $10M Sep 24, 2021
James Cavanaugh Director $739K Nov 13, 2024
Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director $248K Mar 28, 2025
Christopher Mirabelli Chairman of the Board, Director $221K Mar 28, 2025
Augustine Lawlor Chief Operating Officer $221K Mar 28, 2025
Cynthia Sirard Chief Medical Officer $77.6K Mar 28, 2025
John Mark O'Mahony Chief Manufacturing Officer $8.71K Mar 28, 2025
Jason Baum Chief Scientific Officer $5.03K Mar 28, 2025
Christine Granfield VP, Head of Reg Affairs/Qual $5.03K Mar 28, 2025
William Li Director Oct 2, 2024
Nissim Mashiach Director Oct 2, 2024
Richard Schilsky Director Oct 2, 2024
Thomas Dietz Director Oct 2, 2024
Patricia A. Martin Director Oct 2, 2024
Christian M. Richard Director Oct 2, 2024
Monica Bertagnolli Director Jan 31, 2022
Joseph Loscalzo Director Oct 2, 2024

Recent Insider Transactions by Companies or Individuals for Leap Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.